Tattvagene
Tattvagene
A Successful Pregnancy Beings With A Healthy Embryo
Tattvagene is a specialised genetic testing laboratory whose mission is to assist in increaing the chance of having a successful pregnancy and a healthy child. The centre was established 2015, with an aim to offer reliable genetic tests using state-of-the-art technology that would address various needs especially in the Assisted Reproductive Technology (ART) field.
- Parental Karyotyping & Genetic Mutation Tests (Y-chromosome microdeletion, Beta Thalassemia, Spinal Muscular Atrophy, Fragile X Syndrome, etc.)
- Non-invesive Prenatal Screening (NIPS)
- Preimplantation Genetic Screening (PGS)
- Preimplantation Genetic Diagnosis (PGD)
Karyotyping
- Karyotyping is most widely used preliminary test for unexpected infertility.
- The test reveals structural aberrations and aneuploidy
- A source of diagnostic information for genetic disorders and specific birth defects
- This test may be done on a couple having a history of miscarriage or to examine a baby with unusual features or developmental delays
- Recomended before receving assisted reproductive technology (ART)
Fluorescence In Situ Hybridization (FISH)
- A molecular cytogenetic test used in localizing specific DNA sequences on chromosomes
- Gene-specific probs are used to detect presence or absence of a particular gene in metaphase chromosomes/interphase cells
- This helps to detect sub-microscopic chromosomal changes beyond the resolution of karyotyping
Prenatal Diagnosis
- Prenatal karyotyping & FISH are recommended for cases of advanced maternal age, cases with an abnormal result from non-invasive screening, abnormal ultrasound findings or chromosomal aberrations in one of the parents
- Analysis of cultured cells from the amniotic fluid, during the second trimester at 14 to 18 weeks of gestation determines the chromosomal constitution.
PGS
Preimplantation Genetic Screening
- PGS is a diagnostic test used for reducing implantation failures in In Vitro Fertilization (INT) pregnancies
- It helps in selection of normal embryos with a normal chromosome. complement and thus improving INT pregnancy and subsequent live birth rates
Technology
- We use Next Generation Sequencing (NGS) technology to perform PGS
- Detects aneuploidy and mosaicism in the embryos
- Delivers highly detailed, accurate, and scalable. results for improved selection of euploid embryos
NGS
Next Generation Sequencing
Embryo Biopsy
NGS
Intra Cytoplasmic sperm injection with sucking and injecting pipette in position
PGD
Preimplantation Genetic Diagnosis
PGD
Aims to reduce or
eliminate the risk
of inherited
genetic conditions
that either one or
both the parents
are carriers for.
In this procedure the gene that causes the monogenic disorder is sequenced to look for mutations in euploid embryos prior to INT transfer.
PGD with HLA matching
- Beta thalassemia is one of the most common single-gene disorder
- PGD Ivith HLA-typing for the selection of HLA-identical embryos, a therapeutic approach
- This enables the parents to conceive a child who is healthy, as well as a perfect transplant match for their affected child
EMBRYO
Data Analysis & Reporting
Euploid Embryo
Embryo Transfer
NIPS
Non-Invasive Prenatal Screening
A new, safe and highly accurate method to detect common aneuploidies like Down
spidrome, Edwards syndrome and Patau syndrome with a simple blood draw from the
mother.
Technology
- The test analyzes cell-free fetal DNA (cffDNA) which circulates freely in the maternal blood and is used to detect if your baby is at risk for certain genetic conditions
- It is capable of genome-wide aneuploidy detection over the whole foetal genome DNA and gives results for all 23 pairs of chromosomes
- This has a detection rate of 99% and is therefore considered very sensitive
Prenatal Aneuploidy Test
Sample Preparation
Screening
Trisomy 21
Trisomy 18
Trisomy 13
Sex chromosome
Aneuploidy
Personal Risk Scoring
Trisomy 18 (Edwards Syndrome)
Trisomy 21 (Down Syndrome)
The test is capable of genome•ide aneuplady detection over the whole fetal genome (23 pairs of chromosomes) and offers an interpretation of the results for Trisorny 13 Trisomy 18 and Trisomy 21. Th is test confers an accuracy of up to 99% on the detection of fetal chromosome aneuploidy
Trisomy 21 (Down Syndrome)
The test is capable of genome•ide aneuplady detection over the whole fetal genome (23 pairs of chromosomes) and offers an interpretation of the results for Trisorny 13 Trisomy 18 and Trisomy 21. Th is test confers an accuracy of up to 99% on the detection of fetal chromosome aneuploidy
Prenatal Aneuploidy Test Results of Chromosome 13,18 and 21
| Chromosome | Risk | Test Results |
|---|---|---|
| Chromosome 13 Palau Syndrome | - | No aneuploidy detected |
| Chromosome 18 Edwards Syndrome | - | No aneuploidy detected |
| Chromosome 21 Down Syndrome | - | No aneuploidy detected |
Tattvagene lab Test
Tattvagene lab Test Lists
| Test Code | Category | Test | Method | Sample type required | TAT |
|---|---|---|---|---|---|
| TGK001 | Cytogenetics | Karyotyping | GTG banding | Peripheral blood (PB) | 12 - 15 days |
| TGK002 | Cytogenetics | Karytyping + NOR Staining | Silver staining | Peripheral blood (PB) | 12 - 15 days |
| TGK003 | Cytogenetics | Karytyping + C-Banding | Giemsa staining | Peripheral blood (PB) | 12 - 15 days |
| TGY001 | Parental screening | Y Microdeletion - Azoospermia / Oligospermia | PCR/Sanger | Peripheral blood (PB) | 12 - 15 days |
| TGB002 | Parental screening | β-Thalassemia | PCR/Sanger | Peripheral blood (PB) | 12 - 15 days |
| TGF003 | Parental screening | Fragile X Screening | PCR/Sanger | Peripheral blood (PB) | 12 - 15 days |
| TGF004 | Parental screening | Fragile X CGG sizing | Sanger | Peripheral blood (PB) | 12 - 15 days |
| TGT005 | Parental screening | Targeted Testing | PCR/Sanger | Peripheral blood (PB) | 12 - 15 days |
| TGS006 | Parental screening | XY - sex reversal -SRY by PCR | PCR/Sanger | Peripheral blood (PB) | 12 - 15 days |
| TGP007 | Preimplantation screening | Pre-Implantation Genetic Testing for aneuploidies (PGT-A) (per embryo) | NGS | Day 5 Trophectoderm biopsy, 5-6 cells | 15 days |
| TGP008 | Preimplantation screening | Pre-Implantation Genetic Testing for monogenic disorder (PGT-M) (per embryo) | NGS/Sanger | Day 5 Trophectoderm biopsy, 5-6 cells | 15 days |
| TGP009 | Preimplantation screening | PGS + laser biopsy by our embryologist (per embryo) | NGS | Day 5 Trophectoderm biopsy, 5-6 cells | 15 days |
| TGN010 | Prenatal | Non-Invasive Prenatal Screening (NIPS) | NGS | Peripheral blood (PB) | 12 - 15 days |
| TGFS011 | Prenatal | FISH-13/18/21 - Amniotic fluid (10ml) | Fluorescent in situ hybridization | Amniotic fluid | 2 days |
| TGFS012 | Prenatal | FISH LSI 21 - Amniotic fluid (10ml) | Fluorescent in situ hybridization | Amniotic fluid | 2 days |
| TGFS013 | Prenatal | FISH LSI 13 - Amniotic fluid (10ml) | Fluorescent in situ hybridization | Amniotic fluid | 2 days |
| TGFS014 | Prenatal | LSI 13/21 - Amniotic fluid (10ml) | Fluorescent in situ hybridization | Amniotic fluid | 2 days |
| TGFS015 | Molecular Cytogenetics | Sex determining Region Y (SRY)gene by FISH | Fluorescent in situ hybridization | Peripheral blood (PB) | 8 days |
| TGFS016 | Molecular Cytogenetics | FISH - Prader-Willi/ Angelman Region Probe - Microdeletion | Fluorescent in situ hybridization | Peripheral blood (PB) | 12 days |
| TGFS017 | Molecular Cytogenetics | FISH - DiGeorge/ VCFS region probe - Microdeletion | Fluorescent in situ hybridization | Peripheral blood (PB) | 12 days |
| TGFS018 | Molecular Cytogenetics | FISH - DGS2 -10p14 - Microdeletion | Fluorescent in situ hybridization | Peripheral blood (PB) | 12 days |
| TGFS019 | Molecular Cytogenetics | FISH - TBX1 22q11.2 - Microdeletion | Fluorescent in situ hybridization | Peripheral blood (PB) | 12 days |
| TGFS020 | Molecular Cytogenetics | FISH - Tel Vysion 4p - Microdeletion | Fluorescent in situ hybridization | Peripheral blood (PB) | 12 days |
| TGFS021 | Molecular Cytogenetics | FISH - Tel Vysion 1p - Microdeletion | Fluorescent in situ hybridization | Peripheral blood (PB) | 12 days |
| TGFS022 | Molecular Cytogenetics | FISH - 1p36 - Microdeletion | Fluorescent in situ hybridization | Peripheral blood (PB) | 12 days |
| TGFS023 | Molecular Cytogenetics | FISH - Williams Syndrome - Microdeletion | Fluorescent in situ hybridization | Peripheral blood (PB) | 12 days |
| TGFS024 | Molecular Cytogenetics | FISH - Miller - Dieker Chromosome Region Probe (MDS)- Microdeletion | Fluorescent in situ hybridization | Peripheral blood (PB) | 12 days |
| TGFS025 | Molecular Cytogenetics | FISH - Smith - Magenis Chromosome Region Probe (SMS)- Microdeletion | Fluorescent in situ hybridization | Peripheral blood (PB) | 12 days |
| TGFS026 | Molecular Cytogenetics | FISH - Wolf-Hirschhorn syndrome (WHS) - Microdeletion | Fluorescent in situ hybridization | Peripheral blood (PB) | 12 days |
| TGFS027 | Molecular Cytogenetics | Spectral Karyotype (SKY) | Fluorescent in situ hybridization | Peripheral blood (PB) | 15 - 20 days |
| TGFS028 | Molecular Cytogenetics | FISH - X/Y for post bone marrow transplant analysis | Fluorescent in situ hybridization | Peripheral blood (PB) | 4 days |
| TGFS029 | Postnatal Screening | Gauchers Disease -6 common Mutations, exons 9 & 10 | PCR/Sanger | Peripheral blood (PB) | 15 days |
| TGFS030 | Postnatal Screening | Gauchers Disease -complete coding sequence | PCR/Sanger | Peripheral blood (PB) | 15 days |
| TGFS031 | Postnatal Screening | Glycogen Storage Disease - 1a | PCR/Sanger | Peripheral blood (PB) | 15 days |
| TGFS032 | Postnatal Screening | Glycogen Storage Disease - 1b | PCR/Sanger | Peripheral blood (PB) | 15 days |
| TGFS033 | Postnatal Screening | Non Syndromic Hearing Loss - connexin 26 | PCR/Sanger | Peripheral blood (PB) | 15 days |
| TGFS034 | Postnatal Screening | Noonans Syndrome NGS targetted gene panel | PCR/Sanger | Peripheral blood (PB) | 15 days |
| TGFS035 | Postnatal Screening | Achondroplasia -common mutation 1138 G>A/ 1138 G>C | PCR/Sanger | Peripheral blood (PB) | 15 days |
| TGFS036 | Postnatal Screening | HLA typing (6 Loci) | NGS | Peripheral blood (PB) | 25 - 30 days |
| TGFS037 | Postnatal Screening | Spinal muscular atrophy / SMA | PCR/Sanger | Peripheral blood (PB) | 15 days |
Tattvagene lab Test